A liquid biopsy helps to
determine and monitor cancer and other diseases. For the liquid biopsy, blood
or other fluid such as urine is collected and sequenced or analyzed by using
next-generation sequencing (NGS) systems and assays. Tissue biopsy, which is an
invasive procedure, is being replaced by liquid biopsy owing to its efficiency.
Liquid biopsies are a new set of tools in the field of personalized medicine. It
helps to identify the genetics of individuals with cancer, which helps to
mediate the cancer drug dosage plan. An increase in the number of cancer cases
will increase the need for liquid biopsies in the market. The increasing
geriatric population is one of the key factors for the increased adoption of
liquid biopsy tests. Aging causes the immune system of the body to weak. This
makes the majority of the people aged 60 and above prone to chronic diseases
such as cancer and cardiovascular diseases. The occurrence of breast cancer and
colorectal cancer is increasing owing to the increase in the number of older
people. The pandemic of Covid-19 has adversely affected the global economy by
hampering all the industrial sectors and enforcing them to stand still and the
healthcare sector is also not an exception for this. The pandemic of covid-19
has a huge impact on all drug and product development phases, and the strict
regulations of government to mandatorily stay at home, lockdown and social
distancing have imposed most of the companies and clinical research
organizations to put their clinical studies on hold. Infinium Global Research’s recent report on the “Liquid
Biopsy Market (Product - CTCs and ctDNA, and Exosome; End-user - Clinical
Diagnostic Laboratories, Physician’s Office Laboratories, and Hospitals):
Global Industry Analysis, Trends, Size, Share and Forecasts to 2026”
provides a comprehensive outline of the factors responsible for the growth of
the market.
https://www.infiniumglobalresearch.com/reports/sample-request/1300
Hospitals hold the largest market
share for the Liquid
Biopsy Market. They are the key end-users, which highly influences the
market growth. Hospitals include more than 500 beds and provide many inpatient
and outpatient services, thereby generating more revenue. They acquire medical
products and consumables in bulk and engage closely with reimbursement
authorities, suppliers, and government organizations. In the US, the
researchers in hospitals and clinics are focusing on the development of liquid
biopsy products. For instance, the research team at Massachusetts General
Hospital developed a new diagnostic test that can analyze the tumor RNA, which
are picked from the circulating platelets. It is new product development in the
market. The Affordable Care Act (ACA) emphasizes reducing overall hospital
costs, which led hospitals to offer services at lower costs. The government
must pay a few reimbursements to hospitals, which also helps them in generating
revenues. Also, outpatient departments offer better individual care at a low
cost, which can increase the adoption of liquid biopsy testing kits in
hospitals.
https://www.infiniumglobalresearch.com/reports/enquiry/1300
By region, North America holds
the largest share of the Liquid Biopsy market. Owing to the increasing number
of cancer cases, the demand for liquid biopsy will increase in the North
American region. Furthermore, the adoption of technologically advanced products
and the rise in research and development funding/investments are the other key
factors driving market growth. In addition, recent regulatory approvals by
CE for the commercial use of liquid biopsy tests also boosts the market in the
region. The United States and Canada have higher biopsy technologies focusing
on the detection of diseases at early stages, which can significantly reduce the
death rates of these countries. On the other hand, Asia Pacific is likely to be
the fastest-growing region during the forecast period. This is primarily due to
the increasing occurrence of different cancer types, and growth in per capita
health expenditure in countries like China and India.
